Gilead
4Q Revenues: $7.1 billion (-4%)
4Q Earnings: $1.4 billion (-13%)
FY Revenues: $27.1 billion (-1%)
FY Earnings: $5.6 billion (+23%)
Comments: Product sales were down in the quarter due to lower Veklury (remdesivir) and HIV sales, partially offset by higher Oncology sales. Veklury sales were down 28% to $720 million. Descovy sales were down 5% to $509 million in the quarter. Biktarvy sales were up 7% in the quarter to $3.1 billion. Liver Disease portfolio sales were flat at $691 million in the quarter. Cell Therapy product sales increased 11% to $466 million in the quarter. Yescarta sales increased 9% to $368 million. Tecartus sales increased 19% to $98 million. Trodelvy sales increased 53% to $299 million.